Skip to content

Meta-analysis of Soluble Fiber Consumption on Body Weight, Glycemia, and Insulinemia in Overweight and Obese Adults.

Effects of Soluble Fiber Consumption on Body Weight, Glycemia, and Insulinemia in Adults With Overweight and Obesity: a Systematic Review and Meta-analysis of Randomized Controlled Trials.

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03003897
Enrollment
609
Registered
2016-12-28
Start date
2016-01-31
Completion date
2017-10-31
Last updated
2018-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Keywords

Dietary Fiber, Soluble Fiber, Body Mass Index, Body Weight, Blood Glucose, Insulin

Brief summary

Dietary fiber intake is protective against overweight and obesity; however, a significant fiber gap exists between consumption and recommended intake values. Soluble fiber beneficially impacts metabolism, and supplementation may be a feasible approach to improve body composition and glycemia in overweight and obese individuals. The investigators will evaluate results of randomized controlled trials (RCTs) of soluble fiber supplementation among overweight and obese adults for outcomes related to weight management (e.g. body mass index \[BMI\], body weight, body fat percentage, waist circumference) and glucose and insulin homeostasis (e.g. fasting glucose, homeostasis model assessment of insulin resistance \[HOMA-IR\], fasting insulin) through systematic review and meta-analysis.

Interventions

Participants receiving soluble fiber.

OTHERPlacebo

Participants receiving placebo.

Sponsors

University of Illinois at Urbana-Champaign
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Peer-reviewed randomized controlled trials (RCTs) will be included in the systematic review and meta-analysis if they involve participants who are: 1. Overweight or obese (BMI ≥ 25.0 kg/m2 for U.S. populations and ≥ 23.0 kg/m2 for Asian populations and/or waist circumference ≥ 40 inches (94 cm) in men or ≥ 35 inches (80 cm) in women and/or waist-to-hip ratio ≥ 0.90 in men or ≥ 0.85 in women). 2. Weight stable and not actively trying to lose weight at screening. 3. Without physician-diagnosed chronic conditions at screening (e.g., dyslipidemia, hypertension, type 2 diabetes, and cardiovascular disease). 4. Included studies will be soluble fiber supplementation interventions that are controlled feeding studies or conducted among free-living subjects that provide data for outcomes of interest.

Exclusion criteria

Studies will be excluded from the systematic review and meta-analysis if they meet any of the following criteria: 1. Studies conducted in animals. 2. Mechanistic research. 3. Human trials involving pregnant women, breastfeeding women, or children. 4. Conference proceedings. 5. Articles not published in English. 6. Studies less than 1 week in duration. 7. Studies that pool outcome measure data for healthy weight and overweight and obese individuals. 8. Studies involving whole food treatments or high fiber profile diets. 9. Weight loss interventions involving other tactics, such as counseling or energy restriction.

Design outcomes

Primary

MeasureTime frame
Body mass index (kg/m2)≥ 1 week
Body weight (kg)≥ 1 week
Body fat (% fat mass)≥ 1 week
Waist circumference (cm)≥ 1 week
Fasting glucose (mmol/l)≥ 1 week
Fasting insulin (pmol/l)≥ 1 week
Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)≥ 1 week

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 8, 2026